Search

Displaying results 1601 - 1610 of 4438 in total
  1. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.

  2. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. … The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase.

  3. Drug

    Praziquantel

    go.drugbank.com/drugs/DB01058
    ApprovedInvestigationalVet approved

    [A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030

  4. Drug

    Olodaterol

    go.drugbank.com/drugs/DB09080
    ApprovedInvestigational

    Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. … Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs.

  5. Drug

    Isopropamide

    go.drugbank.com/drugs/DB01625
    ApprovedVet approvedWithdrawn

    It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.

  6. Drug

    Indium In-111 pentetate

    go.drugbank.com/drugs/DB09425
    ApprovedInvestigational

    Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column.

  7. Drug

    Calcitriol

    go.drugbank.com/drugs/DB00136
    ApprovedInvestigationalNutraceutical

    In addition to promoting fatty acid synthesis and inhibiting lipolysis, calcitriol has been demonstrated to increase energy efficiency by suppressing UCP2 expression, which is modulated by signaling pathways … Calcitriol plays a role in plasma calcium regulation in concert with parathyroid hormone (PTH) by enhancing absorption of dietary calcium and phosphate from the gastrointestinal tract, promoting renal

  8. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    It was superseded by [pioglitazone] and [rosiglitazone].

  9. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. … Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568]

  10. Drug

    Glycerol phenylbutyrate

    go.drugbank.com/drugs/DB08909
    ApprovedInvestigational

    Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.